Skip to main content

Data Presented at ICPP Show Encouraging Results for Givosiran in AHP Patients

Data Presented at ICPP Show Encouraging Results for Givosiran in AHP Patients
Mathew Shanley
Published Online: Monday, Jun 26, 2017
 2  0  0 Reddit0

At the 2017 International Congress on Porphyrins and Porphyrias (ICPP) this week in Bordeaux, France, Alnylam Pharmaceuticals is presenting new data on Givosiran (ALN-AS1) for the treatment of acute hepatic porphyrias (AHP).

In a randomized, double-blind, placebo-controlled study, Givosiran demonstrates a decreased annualized attack rate and hemin usage. Initial results from an ongoing open-label extension (OLE) study show consistent reductions in porphyria attacks with continued Givosiran treatment.

Hepatic porphyrias are a subgroup of of porphyrias in which the enzyme deficiency occurs in the liver. Acute hepatic porphyrias encompass four diseases: acute intermittent porphyria (AIP) (most common), variagate porphyria, hereditary coproporphyria, and hereditary deficit of delta-aminolevulinic acid dehydratase (most rare).

Currently, urgent treatment with an injection of human hemin and/or perfusion of carbohydrates is required when an acute attack is confirmed. Management of the disorder includes avoiding causal factors to prevent attacks and protect the skin from the light in cases of cutaneous manifestations.

Alnylam’s hope in developing Givosiran, a subcutaneously administered, investigational RNAi therapeutic, is for it to become a novel treatment approach for the prevention of recurrent attacks by targeting ALAS1 for the treatment of AHP, including AIP.

"We believe that a long acting therapeutic agent that has the potential to prevent porphyria attacks and that can be administered via a once monthly, low volume, subcutaneous injection could be a potentially transformative treatment option for patients suffering with this debilitating and potentially life-threatening disease," said Jeff Miller, General Manager of the givosiran program.

"Based on these encouraging interim results and with both Breakthrough Therapy and PRIME designations granted, we will continue to work with global regulatory authorities to rapidly advance givosiran toward regulatory filings and, if approved, to patients. To that end, we remain on track to initiate the givosiran Phase 3 program in late 2017."

Per a press release, the continuing part of the Phase 1 study of the drug is being managed as a randomized, double-blind, placebo-controlled study in up to 24 AIP patients who experience recurrent porphyria attacks. Patients are followed in a 3-month run-in phase, where the amount and frequency of attacks and levels of porphobilinogen (PBG) and aminolevulinate (ALA) are measured prospectively.

Patients who experience at least 1 porphyria attack during the run-in phase are then eligible to enter the study’s 6-month treatment phase, where they are randomized to receive 2 once-quarterly doses or 4 once-monthly doses of placebo or givosiran at 2.5 or 5.0 mg/kg. During the treatment phase, the effects of placebo or givosiran on the number and frequency of porphyria attacks, as well as on the levels of ALA and PBG, are measured prospectively in a blinded manner and then compared to run-in phase results.

Additional measures include safety, tolerability, hospitalizations, use of hemin (FDA approved), levels of ALAS1 mRNA, and givosiran pharmacokinetics. Following the treatment phase, all patients are eligible to receive givosiran in an open-label extension study.

Givosiran has already been granted Orphan Drug Designations in both the E.U. and the U.S. for the treatment of acute hepatic porphyrias. Givosiran also received Breakthrough Designation by the U.S. Food and Drug Administration (FDA), and has been granted PRIME designation by the European Medicines Agency (EMA).

For more updates on orphan drugs, follow Rare Disease Report on Facebook and Twitter.


Popular posts from this blog

Amazing patient advocacy....and needed media for this issue. Thank you Terri Witter!


What could it be?
Nerve Pain WHAT IS NEUROPATHIC PAIN? Neuropathic or nerve pain (NP) is a long-term or chronic pain disease that results from nerve damage. It can be caused by different diseases or conditions. Worldwide nerve pain affects as many as 26 million people. Neuropathic or nerve pain may affect larger areas of the body or it can be restricted to a smaller area, in this case it is called localized neuropathic pain (LNP). WHAT CAUSES NEUROPATHIC PAIN? Neuropathic or nerve pain may occur in the absence of an obvious visible cause (e.g. an accident, an injury, a chemical burn). There are several external situations that can directly damage nerves and lead to neuropathic pain, such as: Amputation of a limb (phantom pain, stump pain)Surgery (scar pain, post-surgery pain)Trauma or accident Neuropathic pain is also a common complication of other diseases, including nerve damage after shingles or herpes zoster infection (postherpetic neuralgia or PHN), nerve damage after HIV infectio…


GLOBAL PORPHYRIA ALLIANCE The APF is proud to support our members that live across the globe. Many countries around the world have developed organizations to support their local communities. We hope that enjoy the same opportunity to communicate with one another, develop friendships, and learn about porphyria. Here are links to patient advocacy groups worldwide that offer support to individuals impacted by porphyria. Argentina: Centro de investigaciones sobre porfirinas y porfirias | More informationAustralia: Porphyria Association, Inc. | More informationBrazil: Associação Brasileira de Porfiria | More informationCanada: Canadian Association for Porphyria | More informationColombia: Fundación Colombiana Para La Porfiria | More informationDenmark: (Porphyria Association Denmark)Denmark: (Danish Porphyria Support Group)England: British Porphyria AssociationFinland: Finnish Porphyria Support Group France: Association Française des Malades Atteints de Por…